Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.72 USD | -13.92% | -10.23% | -56.65% |
Apr. 23 | Top Premarket Decliners | MT |
Apr. 01 | T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2022 | 22.3M | Sales 2023 | 7.19M | Capitalization | 25.42M |
---|---|---|---|---|---|
Net income 2022 | -62M | Net income 2023 | -50M | EV / Sales 2022 | 2.66 x |
Net Debt 2022 | 48.89M | Net Debt 2023 | 33.81M | EV / Sales 2023 | 8.23 x |
P/E ratio 2022 |
-0.12
x | P/E ratio 2023 |
-0.33
x | Employees | 113 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 11.77% |
Latest transcript on T2 Biosystems, Inc.
1 day | -13.92% | ||
1 week | -10.23% | ||
Current month | -9.33% | ||
1 month | -5.23% | ||
3 months | -36.30% | ||
6 months | -47.79% | ||
Current year | -56.65% |
Managers | Title | Age | Since |
---|---|---|---|
John Sperzel
CEO | Chief Executive Officer | 60 | 20-01-07 |
John Sprague
DFI | Director of Finance/CFO | 65 | 18-01-29 |
Roger Smith
CTO | Chief Tech/Sci/R&D Officer | 59 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Elsbree
BRD | Director/Board Member | 76 | 14-06-30 |
Seymour Liebman
BRD | Director/Board Member | 74 | 16-09-20 |
Robin Toft
BRD | Director/Board Member | 63 | 20-06-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 2.72 | -13.92% | 357,900 |
24-04-22 | 3.16 | +6.76% | 1,363,736 |
24-04-19 | 2.96 | -1.00% | 534,565 |
24-04-18 | 2.99 | +1.70% | 106,827 |
24-04-17 | 2.94 | -2.97% | 63,952 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.65% | 27.79M | |
+8.35% | 209B | |
+9.41% | 175B | |
+11.75% | 131B | |
+19.34% | 99.98B | |
-0.84% | 61.12B | |
+15.08% | 52.34B | |
-2.10% | 46.5B | |
+0.10% | 39.24B | |
+11.50% | 38.47B |
- Stock Market
- Equities
- TTOO Stock